Our Stories Rx

"Most rare diseases still lack effective treatments. It’s only logical that the government should allow drug developers to experiment with existing therapies to unlock their full potential."

won't allow for R&D pathways:

Rare Disease Patients Deserve Cures, Too Importing the failed drug policies of countries that ration care and limit treatment options is no solution at all.

"As encouraging as these steps appear, however, past behavior suggests PBMs will work around the new guardrails in the absence of a requirement to act expressly in the interest of employers and patients."

More on the effects of federal reform: https://schaeffer.usc.edu/research/pbm-reform-fair-act-fiduciary/

How much, exactly, is costing you?

"The new calculator enables employer sponsored health plans to estimate potential excess costs associated with 340B program dynamics using company specific and real-time inputs."

Find out more: https://www.prnewswire.com/news-releases/national-alliance-of-healthcare-purchaser-coalitions-launches-calculator-to-reveal-hidden-340b-costs-for-employers-302732934.html